Medarex Partners With GenPat77 To Develop Human Therapeutic Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement adds another player to Medarex’ roster of development partners, which include Bristol-Myers Squibb and J&J.
You may also be interested in...
Medarex Strikes Partnership With Compugen For Oncology and Autoimmune Drug Targets
Firms will share development and commercialization costs associated with products resulting from the agreement.
Medarex Strikes Partnership With Compugen For Oncology and Autoimmune Drug Targets
Firms will share development and commercialization costs associated with products resulting from the agreement.
Medarex Studying Ipilimumab As First-Line Treatment For Metastatic Melanoma
The registrational trial will compare patients treated with ipilimumab and decarbazine with decarbazine alone.